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Objectives: To evaluate reduction whether endoscopic screening reduces mortal-
ity from gastric cancer, a population-based cohort study was performed in Japan, 
where both radiographic screening and endoscopic screening for gastric cancer 
have been conducted. MethOds: The subjects were selected from among partici-
pants in gastric cancer screening in 2 cities (Tottori and Yonago) from 2007 to 2008. 
The subjects were defined as participants aged 40-79 years with no gastric cancer 
screening in the previous year. Follow-up related to mortality was continued from 
the date of the first screening to the date of death or up to December 31, 2013. A 
Cox proportional hazards model was used to estimate the relative risks (RRs) of 
incident gastric cancer, gastric cancer death, all cancer deaths except gastric cancer 
death, and all-cause death except gastric cancer death. Results: The subjects were 
9,950 participants in endoscopic screening and 4,324 participants in radiographic 
screening. The endoscopic screening group showed a 67% reduction from gastric 
cancer compared to that of radiographic screening group (RR adjusted by sex, age 
group, and city of residence = 0.327, 95%CI: 0.117-0.905). The adjusted RR of endo-
scopic screening was 0.966 (95%: 0.674-1.385) for all cancer deaths except gastric 
cancer death and 0.932 (95%:0.742-1.170) for all-cause deaths except gastric cancer 
death. cOnclusiOns: The results of the present study suggest that endoscopic 
screening can decrease mortality from gastric cancer by 67% compared with radio-
graphic screening. The results are consistent with the previous studies that showed 
that endoscopic screening reduces mortality reduction from gastric cancer.
PCN13
TheraPy Of DePressiON iN CaNCer aND NON-CaNCer PaTieNTs iN 
GermaN NeurOPsyChiaTriC PraCTiCes
Ziegelbauer K, Engelhard J, Kostev K
IMS Health, Frankfurt am Main, Germany
Objectives: It is known that patients with cancer are more at risk of becoming 
depressant. However, there is lack of information about how these patients are 
treated. The purpose of this study was to investigate if cancer patients are treated dif-
ferently to non-cancer depression patients. MethOds: Using IMS® Disease Analyzer, 
patients were selected who were initially diagnosed with depression following cancer 
diagnosis between January 2004 and December 2013 from neuropsychiatrists (NP). 
Based on age, gender, health insurance and index year patients with prior cancer 
diagnosis were matched with a control group of patients who had no cancer diag-
nosis. The share of patients with a medical therapy within one year after depres-
sion diagnosis and the proportion of patients treated with tricyclic antidepressant 
(TA), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine 
reuptake inhibitors (SSRNI) or benzodiazepines (BZD) were analyzed. Results: The 
study population consisted of 604 depression patients with and 604 without cancer 
(mean age 63.8 years, 36.5% male, 6.0% with private health insurance). In the cohort 
of cancer patients 27.6% had a breast cancer, 13.3% malignant neoplasms of lymphoid 
or hematopoietic tissue, 12.5% brain tumor, 8.3% prostate cancer, 10.0% cancer of 
digestive organs. 66.5% of patients with cancer and 72.8% without cancer received 
prescriptions of antidepressant drug (p= 0.017). There were no significant differences 
in shares of SSRI/SSNRI (32.7% of cancer and 34.1% of non-cancer patients). TA were 
given less often in cancer patients (31.2% versus 38.2%, p= 0.011), BZD slightly more 
often in cancer patients (7.0% versus 4.2%, p= 0.033). cOnclusiOns: Our studies 
showed that cancer patients receive slightly less and different antidepressant drug 
treatment than non-cancer patients. In further studies it should be analyzed what 
the reasons for the treatment decisions and what the patient health outcomes are.
PCN14
LONG-Term TreNDs iN DesCriPTive ePiDemiOLOGy Of maLiGNaNT 
meLaNOma iN The sLOvak rePubLiC
Ondrusova M, Psenkova M, Suchansky M
Pharm-In Ltd, Bratislava, Slovak Republic
Objectives: The latest available national data from the Slovak Republic (SR) are for 
year 2008. The objective of this paper was to analyze and prospectively predict long-
term national trends of malignant melanoma (MM) incidence, mortality, clinical 
stages and prevalence to obtain more actual data for the purpose of cost-of-illness 
studies and budget impact analysis in the SR. MethOds: Time-trends of national 
data on incidence, mortality, clinical stages and prevalence of MM in 1968-2008 
were analyzed by using joint-point regression (Version 4.1.1.5). The data were pre-
dicted to the current year 2015. The trends are presented with a corresponding 95% 
Confidence Intervals (CI) and p-value with null hypothesis being constant with 
time. Results: Epidemiological trends: In males (y.2008), MM age-standardized 
incidence represented 9.0/100,000 (n= 315 cases, mean age= 63.8 y.), with the last 
annual percentage change (APC) of 5.3% in 1995-2008 (95%CI= 3.5-7.1, p< 0.0001), 
estimated incidence for 2015 is 13.49/100,000 (95%CI ±0.637). Mortality in 2008 rep-
resented 2.3/100,000 (n= 85) with the last APC 2.2% (95% CI= 1.6-2.8, p< 0.0001), esti-
mation 2015 is 3.15/100,000 (95%CI ±0.159). In females (y.2008), MM incidence was 
7.5/100,000 (n= 330, mean age= 60.27 y.), with the APC 3.5% (1968-2008, 95%CI= 3.1-
3.8, p< 0.0001), estimation 2015 is 10.55/100,000 (95%CI ±0.164). Mortality in 2008 
represented 1.5/100,000 (n= 74), APC 0.53% in 1988-2008 (95% CI= -0.6-1.6, p= NS), 
estimation 2015 represents 1.73/100,000 (95%CI ±0.378). National prevalence in 2015 
for both sexes represents 8.626 cases. We estimate 65.6% patients diagnosed in the 
1st clinical stage, 22.44% in the 2nd, 1.54% in the 3rd, 6.03% in the 4th and 0.18% 
in the undefined clinical stage. The number of cases in the 1st stage is increasing 
during the time, however, the 4th stage remains stable. cOnclusiOns: Actual data 
on prevalence and clinical stages of MM in the SR can be used as the source for set-
ting the size of population in cost-of-illness studies and budget-impact analysis.
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PaTTerNs Of meTaChrONOus meTasTases afTer CuraTive TreaTmeNT Of 
breasT CaNCer
Kuiper JG1, van Herk-Sukel MP1, van Gestel YR2, Voogd AC3, Lemmens VE4, Siesling S5
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Comprehensive 
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rospective study was based on the National Health Insurance Fund Administration 
financing database. The study period spanned between 01.01.2005 and 12.31.2014. 
Several oncological fields were investigated: lung cancer (ICD C34), prostate cancer 
(ICD C61), kidney cancer (BNO C64-C65), breast cancer (ICD C50), haematopoietic 
and lymphatic system cancer (ICD C81-85, C88, C90-96) and colorectal cancer (ICD 
C18-C20). The trends in overall survival (OS) have been computed and compared for 
each subgroups using Cox proportional hazard models. Results: In general there 
was found that age, metastatic stage and comorbidities were the most relevant 
covariates in all groups. Analysing trends of mortality there is a difference between 
patients who were diagnosed in 2007 comparing to those who were diagnosed in 
2011. cOnclusiOns: The magnitude of the fitted trends could be very different, 
the precise reasons of the differences and the difference of cost, the relative risk of 
the mortality, and the comorbidity effects within the variant disease groups should 
be further investigated. The applied framework methods can serve both direct com-
parison and forecasting models in care management, e.g. Disability-Adjusted Life 
Year, Quality-Adjusted Life Years, Years of Potential Life Lost.
PCN10
PrevaLeNCe Of DePressiON aND aNxieTy aND Their risk faCTOrs iN 
WOmeN WiTh breasT CaNCer iN GermaN Primary Care
Engelhard J1, Bleicher L2, Kostev K1
1IMS Health, Frankfurt am Main, Germany, 2University Clinic of Marburg, Marburg, Germany
Objectives: Although the psychological effect of breast cancer (BC) diagnosis is 
well documented, less is known about the prevalence of, and risk factors for depres-
sion and anxiety in the BC patients. MethOds: Women initially diagnosed with 
breast cancer (ICD 10: C50) between January 2009 and December 2013 (indexdate) 
were identified from 1,202 general practitioner’s (GP) and 244 gynecologist’s (GYN) 
practices in the IMS Disease Analyzer database. Patients were included only if they 
did not have any diagnosis of depression or anxiety within 12 months before index 
date.. The main outcome measure was the first diagnosis of either depression or 
anxiety disease within one year after indexdate. A total of 23,709 patients at GPs 
and 19,977 at GYN were available for the analysis. Results: Baseline characteris-
tics of study patients were as follows: mean age was 64.3 years, 9% had a private 
health insurance, 9.4% of patients had a metastatic BC. After 1 year of follow-up, 
17.4% of patients at GPs and 19.2% at gynecologists were diagnosed with depres-
sion or anxiety. There was a significantly higher risk of depression/anxiety in the 
age groups 41-50 (HR: 1.27, p< 0.001) and 51-60 (HR: 1.30, p< 0.001) compared to 
< = 40 years. There was a much higher risk of depression/anxiety in patients with 
metastatic breast cancer (HR: 1.20, p< 0.001) and patients with depression/anxiety 
episodes in the past (> 1 year prior to indexdate (HR: 1.91, p< 0.001). Private health 
insurance was associated with a significantly lower depression/anxiety risk (HR: 
0.43, p< 0.001). cOnclusiOns: Analysis of real-world data from German primary 
care practices identified potential risk factors for the development of depression/
anxiety disorder among BC patients. Being aware of these risk factors could facili-
tate early prevention and support for affected patients with potentially beneficial 
implications for their overall therapy. Further research has to be done to investigate 
these risk factors in more detail.
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The effeCT Of GLuCOse LOWeriNG DruG use ON OveraLL mOrTaLiTy 
amONG breasT CaNCer PaTieNTs
Vissers PA1, Zanders MM2, Voogd AC3, van Herk-Sukel MP4, Ruiter R5, Hollestein LM5, 
Herings RM4, Stricker BH5, van de Poll-Franse LV2
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Objectives: This study assesses the effect of glucose lowering drug (GLD) use, i.e. 
metformin, sulfonylurea derivatives (SUs), insulin and other GLDs, started after 
breast cancer diagnosis, on overall mortality. MethOds: All female breast can-
cer patients diagnosed between January 1st, 1998 and December 31st, 2011 who 
started using GLDs after breast cancer diagnosis, were included. Clinical charac-
teristics were derived from the Netherlands Cancer Registry, drug dispensing data 
from the PHARMO Database Network and data on overall mortality from the Dutch 
municipal personal records database. Time-dependent Cox regression analysis, 
with cumulative exposure to GLDs were conducted to assess effects on overall 
mortality. Results: In total, 407 breast cancer patients were included. Most women 
(n= 335, 82%) used metformin at some point during follow-up, followed by SUs 
(n= 202, 50%), insulin (n= 58, 14%) and other GLDs (n= 41, 10%). The average follow-up 
was 7.7 ± 3.6 years and 107 (26%) patients died during follow-up. Adjusted analyses 
showed that metformin users had a lower overall mortality (HR= 0.47; 95%CI:0.29-
0.74), while insulin users had a higher overall mortality (HR= 1.85; 95%CI:1.09-3.15) 
compared to non-users. However, when assessing dose-response effects no asso-
ciation was found between cumulative use of metformin, SU, insulin or other GLDs 
and mortality. cOnclusiOns: GLDs were not associated with mortality among 
patients who started using GLDs after breast cancer diagnosis. We did observe a 
lower mortality among breast cancer patients using metformin and higher mortal-
ity among patients using insulin. However, as no dose-response relationship was 
observed, the found effects on mortality are likely to result from differences in 
patient characteristics that we could not adjust for and not from the drugs itself. 
Larger studies with longer follow-up among patients who start using GLDs after 
cancer diagnosis are needed to confirm our findings.
PCN12
mOrTaLiTy reDuCTiON frOm GasTriC CaNCer by eNDOsCOPiC sCreeNiNG: 
6-years fOLLOW-uP Of a POPuLaTiON-baseD COhOrT sTuDy
Hamashima C1, Shabana M2, Okada K3, Okamoto M4, Osaki Y4
1National Cancer Center, Tokyo, Japan, 2San-in Rosai Hospital, Yonago, Japan, 3Tottori East 
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tively. DISCUSSION : In absence of head-to-head trials, indirect comparisons can 
provide useful insights to clinicians and reimbursement-decision making on relative 
efficacy of treatments. The probabilistic interpretation of Bayesian results suits these 
purposes, allowing probabilistic statements on which treatment is likely to be the 
most effective. Bayesian probabilities and credible intervals have different interpre-
tation than classical p-values and confidence intervals. Bayesian results fit well in 
decision modelling, as resulting posterior distributions can serve as priors in proba-
bilistic cost-effectiveness modelling. Assumptions behind NMA to generate unbi-
ased results were considered valid for IBR vs IDEL+OFA-comparisons, as included 
patient-populations were nearly identical. Estimates versus PC may be conservative, 
given higher relative treatments effect in more severe patients. cOnclusiOns: 
In absence of direct evidence, NMA-results suggest improved PFS and OS for IBR 
compared to IDEL+OFA and to PC in R/R CLL-patients with high certainty, and can 
serve as input in HTA-decision modelling.
PCN18
assessmeNT Of majOr mOLeCuLar resPONse (mmr) aND COmPLeTe 
CyTOGeNeTiC resPONse (CCyr) as surrOGaTe OuTCOmes Of survivaL iN 
ChrONiC myeLOiD Leukemia ChrONiC Phase (CmL-CP) PaTieNTs
Kwon H, Park J, Shin M, Shin S
National Evidence based Health-care Collaborating Agency, Seoul, South Korea
Objectives: This study aims to investigate the association of the major molecular 
response (MMR) and complete cytogenetic response (CCyR) as surrogate outcomes 
with overall survival (OS) and progression free survival (PFS) in chronic phase of 
chronic myeloid leukemia (CML-CP) patients using evidence from observational or 
experimental study. MethOds: We conducted using existing systematic reviews 
and meta-analysis to quantify the association between CCyR and/or MMR at 12 
months and OS and/or PFS. The overall survival rate or progression free survival rate 
according to the responders or non-responders of MMR or CCyR at 12 months after 
the initiation of first-line TKI therapy (imatinib, dasatinib or nilotinib) was extracted 
by two independent reviewers. A weighted average of the OS and PFS at differ-
ent yearly intervals was estimated respectively for both the responders and non-
responders with assumption of no censoring. The analyses were carried out using 
R package “metafor”. Results: Eleven studies provided data on the association 
between CCyR or MMR and OS or PFS after imatinib treatment however there were 
no such studies about dasatinib or nilotinib treatment. Patients who experience 
CCyR following 12 months’ TKI therapy have better long-term (7 –year) OS and PFS 
(OS 97.0% vs 82.5; PFS 97.0% vs 69.6%) than patients who are non-responders at 12 
months. Patients who experience MMR at 12 months’ TKI therapy have better long-
term (5-year) OS and PFS (OS 99.4% vs 93.4%; PFS: 89.9% vs 85.3%). cOnclusiOns: 
This study identified evidence of the association between CCyR and/or MMR and 
survival among the TKI treated CML-CP patients, and this is based entirely on 
imatinib treatment studies. The evidence of dasatinib and nilotinib is limited by 
the amount and quality of data available. Therefore further research is needed 
whether this relationship between the surrogate outcomes and final outcomes are 
equally applicable to dasatinib and nilotinib.
PCN19
COmParisON Of TreaTmeNT DuraTiON amONG TarGeTeD aGeNTs iN 
reNaL CeLL CarCiNOma (rCC)
Feinberg BA1, Bohr M1, Drenning J2, Garofalo DF1, Montgomery J2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA
Objectives: Conducting comparative effectiveness research among multiple 
classes of treatments may inform optimal treatment based on the real-world 
effectiveness. We conducted a retrospective analysis comparing the duration of 
six leading treatment options in renal cell carcinoma stratified by line of ther-
apy. MethOds: Using claims data (MORE2 Registry), patients with renal cell car-
cinoma who started and completed at least one line of treatment during the study 
period (January 2012 to February 2014) were identified by ICD9 code 189.0. Line 
of therapy (LOT) was assigned based on the patient’s available treatment history. 
Analysis was stratified by LOT. Univariate analysis of variance was performed to 
compare mean durations among treatment options, LOT, and therapeutic class. 
Multivariate analysis controlling for demographic and treatment characteristics 
will be presented in the poster. Results: Patients received 1240 complete lines 
of therapy. Mean duration of treatment by line of therapy was as follows: 1st LOT: 
4.0 mo (n= 599); 2nd LOT: 3.2 mo (n= 357); 3rd LOT 3.1 mo (n= 284). There was sta-
tistically significant difference in mean duration of therapy between the groups of 
patients by second line regimen (p= 0.003). Within the second line patient group 
the tyrosine kinase inhibitor (TKI) treated patients had greater duration compared 
to the mammalian target of rapamycin (mTOR) treated patients (3.5 mo vs 2.6 
mo, p-value= 0.006). However no difference in duration was observed among first 
(p= 0.7239) and third line regimens (p= .0.6476). cOnclusiOns: In this study there 
was statistically significant difference in duration among leading systemic agents 
used for second-line treatment of RCC where patients were shown to remain on 
TKI treatment longer than mTOR treatment. Future research should determine if 
toxicity and costs influence duration in this therapeutic area.
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evaLuaTiON Of PaTTerNs Of Care iN reNaL CeLL CarCiNOma (rCC): hiGh 
uNmeT NeeD PersisTs
Feinberg BA1, Bohr M1, Drenning J2, Garofalo DF1, Montgomery J2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA
Objectives: Understanding prescriber perceptions of efficacy and tolerability 
among available RCC treatments in a real-world population may inform current 
areas of unmet need and provide context for the adoption of new therapeutics. We 
conducted a retrospective analysis evaluating the drug utilization patterns and 
duration of tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin 
(mTOR) inhibitors in patients with newly diagnosed and relapsed RCC. MethOds: 
Using claims data (MORE2 Registry), patients with RCC who completed at least one 
Maastricht, The Netherlands, 4Netherlands Comprehensive Cancer Organisation, Eindhoven, The 
Netherlands, 5Comprehensive Cancer Centre the Netherlands (IKNL), Enschede, The Netherlands
Objectives: To evaluate the patterns of metachronous metastases in patients with 
breast cancer. MethOds: Patients diagnosed with non-metastatic (M0) breast cancer 
at initial diagnosis between 2006-2008 were selected from the Eindhoven Cancer 
Registry, which is a population-based registry and records data on newly diagnosed 
cancer patients. By means of active follow-up, additional data on date of diagnosis 
and localization of metachronous metastases were collected directly from the patient 
files. Anatomical sites of metastasis were registered according to the International 
Classification of Diseases for Oncology (ICD-0). Proportions of metachronous metas-
tases between tumour and treatment characteristics were compared using the Chi2 
test. A p-value < 0.05 was considered significant. Results: There were 1,382 patients 
diagnosed with M0 breast cancer with a mean (±SD) age of 60.3 (±13.8) years. Of those, 
116 patients (8%) developed metachronous metastases during a median (±SD) follow-
up of 4.1 (±1.1) years. The mean (±SD) age at the time of diagnosis of metachronous 
metastases was 61.7 (±14.3) years. Diagnosis of metachronous metastases was con-
firmed by imaging in 76 patients (66%), in 39 patients (34%) by histopathology and 1 
patient (1%) based on clinical symptoms. The most frequent metastatic sites affected 
were bone (29%) and liver (17%). Breast cancer patients who developed metachro-
nous metastases were significantly more often diagnosed with a hormone recep-
tor positive and a HER2-negative tumor, had a poor tumor grade, had a tumor size 
greater than 2.1 cm, and more often received chemotherapy at initial breast cancer 
diagnosis. cOnclusiOns: Of the initially M0 breast cancer patients, 8% developed 
metachronous metastases, of which one-third developed bone metastasis. The risk 
of developing metachronous metastases varies among different characteristics at 
initial breast cancer diagnosis. Identifying the patterns of metachronous metasta-
ses and characteristics increasing the risk for developing metachronous metastases 
contributes to tailored follow-up and adequate initial M0 breast cancer treatment.
PCN16
TreaTmeNT sTraTeGies fOr eLDerLy PaTieNTs WiTh NeWLy DiaGNOseD 
muLTiPLe myeLOma: a meTa-aNaLysis aND iNDireCT TreaTmeNT 
COmParisON
Buchberger M1, Rochau U2, Vukicevic D1, Willenbacher W3, Siebert U4
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Objectives: Elderly patients with newly diagnosed multiple myeloma (MM) 
are usually not considered for stem cell transplantation. Treatment alternatives 
include multidrug regimens combining prednisone (P)/dexamethasone (D), tha-
lidomide (T), bortezomib (V), cyclophosphamide (C), and melphalan (M). Head-to-
head comparisons between the different treatments are lacking. We compared 
the effectiveness of different first-line treatment strategies for patients with 
MM (age > 65 years) in terms of progression-free survival (PFS) and overall sur-
vival (OS). MethOds: We performed a systematic literature search in MEDLINE, 
EMBASE, Cochrane Library and CRD databases. The primary search yielded 2,673 
citations. Ten randomized controlled trials (RCT), enrolling a total of 3,782 patients, 
were included in our meta-analysis and indirect treatment comparisons. We calcu-
lated pooled hazard ratios (HR) with 95% confidence intervals (95%CI). Results: 
Meta-analysis of six RCTs comparing MPT vs. MP showed a statistically significant 
benefit of MPT in PFS (HR 0.75, 95%CI 0.64-0.88) but no statistically significant dif-
ference in OS (HR 0.90, 95%CI 0.75-1.08). The indirect comparison of MPT vs. MPV 
showed a benefit in PFS for MPV (HR 1.41, 95%CI 1.04-1.90) but no OS difference 
(HR 1.29, 95%CI 0.98-1.70) using MP regimen as the common comparator. There 
was no difference between MPT vs. CTD, indirectly analyzed with MP as common 
comparator (PFS: HR 0.91, 95%CI 0.73-1.14; OS: HR 1.01, 95%CI 0.78-1.32). Indirect 
comparison was also possible for VMPT-VT vs. VTD, both compared to MPV in 
the original RCTs. VMPT-VT showed a statistically significant benefit in PFS (HR 
0.48, 95%CI 0.33-0.71) but no difference in OS (HR 1.04, 95%CI 0.69-1.59) compared 
to VTD. cOnclusiOns: While some regimens showed improved PFS, there was 
no evidence for a benefit in OS comparing the different treatment strategies. 
Combining all treatment strategies based on published data by using a network 
meta-analysis may help to identify the optimal treatment option.
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bayesiaN NeTWOrk meTa-aNaLysis TO assess reLaTive effiCaCy Of 
ibruTiNib versus iDeLaLisib+OfaTumumab aND PhysiCiaN’s ChOiCe iN 
reLaPseD/refraCTOry CLL PaTieNTs
Diels J1, van Sanden S2
1Janssen Research & Development, Beerse, Belgium, 2Janssen EMEA, Beerse, Belgium
Objectives: To assess the relative efficacy of ibrutinib (IBR), a first-in-class BTK- 
inhibitor, versus Idelalisib+ofatumumab (IDEL+OFA) and physician’s choice in 
relapsed/refractory (R/R) CLL-patients using Bayesian Network Meta-Analysis 
(NMA). MethOds: Three RCTs in R/R CLL-patients were identified with OFA as 
common treatment arm. IBR (Byrd, 2014) and IDEL+OFA (Jones, 2015) showed 
improved investigator-assessed PFS (HR= 0.13 and 0.27, respectively) and OS 
(HR= 0.39 and 0.74, respectively) versus ofatumumab in R/R CLL-patients. Osterberg 
(2014) compared PFS (INV) (HR= 0.56) and OS (HR= 0.72) for OFA to physician’s 
choice (PC), a mix of well-established CLL-treatments, in more severe patients. A 
Bayesian NMA was conducted in line with NICE guidelines, using a fixed-effect 
model with non-informative priors. Posterior distributions for the HR were sum-
marized by median values and 95% credible intervals. Results: HR for PFS (INV) 
comparing IBR vs IDEL+OFA and PC were 0.49 ([0.28;0.87],P(HR< 1)= 99.2%) and 0.07 
([0.04;0.13],P(HR< 1)= 100%), respectively. HR for OS comparing IBR vs IDEL+OFA and 
PC were 0.52 ([0.24;1.14],P(HR< 1)= 94.7%) and 0.28 ([0.13;0.80],P(HR< 1)= 100%), respec-
